Boston Scientific's EKOS System Shows Superiority in HI-PEITHO Trial for Acute Pulmonary Embolism
BSX is trading near its 52-week low of $67.56 (2.7% above the low).
Summary
Boston Scientific announced highly positive results from its HI-PEITHO global randomized clinical trial, demonstrating that its EKOS Endovascular System, combined with anticoagulation, was superior to standard anticoagulation alone for treating intermediate-risk acute pulmonary embolism. This is a significant clinical validation for the EKOS system, a minimally invasive intervention that delivers clot-dissolving medication directly to the clot. This news is distinct from earlier positive trial results for the WATCHMAN FLX device reported today, highlighting the company's robust product development pipeline. The demonstrated superiority could drive increased adoption, potentially leading to expanded market share and revenue growth for Boston Scientific, particularly as the stock trades near its 52-week low. Traders will monitor for regulatory filings and commercialization plans.
At the time of this announcement, BSX was trading at $69.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $102.6B. The 52-week trading range was $67.56 to $109.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: dpa-AFX.